ADC Therapeutics SA
ADCT$544M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaEPALINGES263 employees
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Mar 31, 2026
3dMarket Overview
Stock performance and key metrics
ADCT News
Catalyst Timeline
1 upcoming, 3 past
Phase 3Next
Loncastuximab Tesirine Phase 3 Results Expected
Mar 31, 2026EstimatedLoncastuximab Tesirine440
Primary completion for Loncastuximab Tesirine trial (NCT04384484) in Relapsed Diffuse Large B-Cell Lymphoma
SourceDrug Pipeline
Loncastuximab Tesirine
Relapsed Diffuse Large B-Cell Lymphoma
Camidanlumab Tesirine
Relapsed Hodgkin Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Loncastuximab Tesirine | Phase 3 | Relapsed Diffuse Large B-Cell Lymphoma | - | - |
Camidanlumab Tesirine | Phase 2 | Relapsed Hodgkin Lymphoma | - | - |
Relapsed Hodgkin Lymphoma
1 drug in this indication
Relapsed Diffuse Large B-Cell Lymphoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply